Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to -$399799.0.

  • China Pharma Holdings' Net Cash Flow fell 119430.87% to -$399799.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$417862.0, marking a year-over-year increase of 3777.53%. This contributed to the annual value of -$764365.0 for FY2024, which is 1979.55% down from last year.
  • As of Q3 2025, China Pharma Holdings' Net Cash Flow stood at -$399799.0, which was down 119430.87% from $254149.0 recorded in Q2 2025.
  • China Pharma Holdings' 5-year Net Cash Flow high stood at $4.4 million for Q4 2021, and its period low was -$1.4 million during Q2 2022.
  • Over the past 5 years, China Pharma Holdings' median Net Cash Flow value was -$65874.0 (recorded in 2024), while the average stood at -$20401.8.
  • As far as peak fluctuations go, China Pharma Holdings' Net Cash Flow surged by 929863.04% in 2023, and later crashed by 183509.07% in 2024.
  • China Pharma Holdings' Net Cash Flow (Quarter) stood at $4.4 million in 2021, then plummeted by 101.36% to -$60201.0 in 2022, then skyrocketed by 105.86% to $3528.0 in 2023, then plummeted by 1835.09% to -$61214.0 in 2024, then tumbled by 553.12% to -$399799.0 in 2025.
  • Its last three reported values are -$399799.0 in Q3 2025, $254149.0 for Q2 2025, and -$210998.0 during Q1 2025.